CNS Pharmaceuticals, Inc. Deferred Offering Costs
CNS Pharmaceuticals, Inc. (CNSP) had Deferred Offering Costs of $73.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2026-08-12
- 2026-06-30: Deferred Offering Costs $73.00K.
- 2026-03-31: Deferred Offering Costs $27.25K.
- 2025-12-31: Deferred Offering Costs $45.00K; Deferred Offering Costs as first filed $45.49K.
- 2025-09-30: Deferred Offering Costs $43.70K.
| Period end | Deferred Offering Costs | Deferred Offering Costs as first filed |
|---|---|---|
| 2026-06-30 | $73.00K 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $27.25K 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $45.00K 10-Q · filed 2026-08-12 | $45.49K 10-K · filed 2026-03-31 |
| 2025-09-30 | $43.70K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $14.17K 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $20.64K 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $20.64K 10-K · filed 2026-03-31 | |
| 2024-09-30 | $26.93K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $16.75K 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $202.86K 10-K · filed 2025-03-31 | |
| 2022-12-31 | $0.00 10-K · filed 2024-04-01 | |
| 2022-09-30 | $334.14K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $334.14K 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $334.14K 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $334.14K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $334.14K 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $334.14K 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $334.14K 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $334.14K 10-K · filed 2022-03-03 | |
| 2020-09-30 | $440.90K 10-Q · filed 2020-11-12 | |
| 2019-12-31 | $0.00 10-K · filed 2021-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |